Sunny Pharmtech Inc. (TPEX:6676)

Market Cap	2.07B -6.0%
Revenue (ttm)	253.01M -39.5%
Net Income	-302.05M
EPS	-2.03
Shares Out	148.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,914
Open	13.80
Previous Close	13.75
Day's Range	13.70 - 14.20
52-Week Range	12.95 - 19.85
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Sunny Pharmtech

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for bloo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 158
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6676

Financial Performance

In 2025, Sunny Pharmtech's revenue was 253.01 million, a decrease of -39.47% compared to the previous year's 418.01 million. Losses were -302.05 million, 93.6% more than in 2024.